Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
DE000A3DSV01
Fri, 06.12.2024
Cantourage Group SE
Company Name:
Cantourage Group SE
ISIN:
DE000A3DSV01
Reason for the research:
Update
Recommendation:
BUY
from:
06.12.2024
Target price:
11.50
Target price on sight of:
12 months
Last rating change:
Analyst:
Christian Sandherr
Full steam ahead, FY24 guidance raised; PT up
Topic: Cantourage raised its FY24e guidance following co [ … ]
Tue, 28.05.2024
Cantourage Group SE
Debottlenecking production capacities
Topic: Cantourage and Portocanna entered into a strategic partnership which
offers Cantourage a capital light way to increase its production capacities
significantly amid the surging demand for medical cannabis in Germany.
Legalization light is transforming the market. As of the beginning of
April, cannab [ … ]
Fri, 17.05.2024
Cantourage Group SE
Solid FY23 and Q1'24 prelims // accelerating growth in April; chg.
Topic: Cantourage issued solid FY23 and Q1 2024 prelims, which were
impacted by slower patient growth amid the looming (at that time)
regulatory changes. Sales figures for April (following legalization light)
show a significant acceleration.
FY23 sales grew by 67% yoy to &euro [ … ]
Tue, 06.02.2024
Cantourage Group SE
Cannabis legalization around the corner
Topic: With the approval of the 'Cannabis Act', which is now expected to
take place at the beginning of April, Germany is seen to take a big leap
forward in regards to legalizing cannabis. This should translate into a
significant tailwind for players such as Cantourage.
As per consistent and reliable Ge [ … ]